|
|
|
| home > ebr > spring 2004 > a review of burrill & company's 18th annual report on the biotech industry |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| "While revaluation and restructuring defined 2002, the biotech industry made a dramatic recovery in 2003 getting 'back on track'", notes G Steven Burrill at the start of Burrill & Company's 18th annual report on the biotechnology industry. The 450 page compendium details all the important events, discoveries and financial activity in the various sectors of the biotechnology industry during 2003. G Steven Burrill, CEO of Burrill & Company and a respected biotech investment visionary, identifies the key trends and outlook for this increasingly vital and important industry. Burrill's book is a valuable resource of state-of-the-industry data and statistics with insight on where the various areas of the life sciences are headed. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
BioPartnering Latin America
11-13 September 2012, Rio de Janeiro, Brazil
BPL 2012 will support a dynamic and global biotechnology-based industry to provide a unified platform for policymaking, business collaboration and funding opportunities in Latin America.
More info >> |
|
 |
News and Press Releases |
 |
AstraZenenca teams up with GS1 UK for coding solutions
AstraZeneca is working with GS1 UK, a not-for-profit industry standards body, to use unique identification codes and sophisticated 2 Dimensional (2D) barcodes to keep automated records of dispensing information, expiry dates, batch validity and to monitor how pharmaceuticals move through the supply chain, helping reduce the risk of patients being given counterfeit or substandard medicines.
More info >> |
|
|
